Cost per responder associated with biologic therapies for crohn's disease, psoriasis, and rheumatoid arthritis

Advances in Therapy

Volumn 29, Issue 7, 2012, Pages 620-634

  Liu, Yifei ^a   Wu, Eric Q ^b   Bensimon, Arielle G ^b   Fan, Chun Po Steve ^b   Bao, Yanjun ^c   Ganguli, Arijit ^c   Yang, Mei ^c   Cifaldi, Mary ^c   Mulani, Parvez ^c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b ANALYSIS GROUP   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Biologic therapy; Cost per remitter; Cost per responder; Cost effectiveness; Crohn's disease; Psoriasis; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; TOCILIZUMAB; USTEKINUMAB;

ARTICLE; BIOLOGICAL THERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; HUMAN; META ANALYSIS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG COSTS; HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866541262     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0035-7     Document Type: Article

References (40)

1. Gartlehner G, Thieda P, Morgan LC, Thaler K, Hansen RA, Jonas B Drug Class Review: Targeted Immune Modulators: Final Report Update 2 Portland, OR: Oregon Health & Science University; 2009.
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States Clin Gastroenterol Hepatol 2007;5:1424-9.
3. Loftus EV Jr, Schoenfeld P, Sandborn WJ The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review Aliment Pharmacol Ther 2002;16:51-60.
4. National Psoriasis Foundation Benchmark survey on psoriasis and psoriatic arthritis: summary of top-line results Available at: http://www.psoriasis.org/ files/pdfs/press/npfsurvey.pdf Accessed December 15, 2010.
5. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y The psychosocial burden of psoriasis Am J Clin Dermatol 2005:6:383-92.
6. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 1999;41:401-7.
7. Helmick CG, Felson DT, Lawrence RC, et al National Arthritis Data Workgroup Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I Arthritis Rheum 2008;58:15-25.
8. Cohen M, Morrow T, Penna P Managing the expanded use of biologics across therapeutic areas: an example from B-cell targeted therapies Am J Manag Care 2006;12:S24-37.
9. Griffiths CE, Strober BE, van de Kerkhof P, et al ACCEPT Study Group Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 2010;362:1 18-28.
10. Schiff M, Keiserman M, Codding C, et al Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate Ann Rheum Dis 2008;67:1096-103.
11. Colombel JF, Sandborn WJ, Rutgeerts P, et al Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 2007;132:52-65.
12. Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 2002;359:1541-9.
13. Saurat JH, Stingl G, Dubertret L, et al CHAMPION Study Investigators Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION) Br J Dermatol 2008;158:558-66.
14. Menter A, Tyring SK, Gordon K, et al Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 2008;58:106-15.
15. Papp KA, Tyring S, Lahfa M, et al Etanercept Psoriasis Study Group A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction BrJ Dermatol 2005; 152:1304-12.
16. Leonardi CL, Powers JL, Matheson RT, et al Etanercept Psoriasis Study Group Etanercept as monotherapy in patients with psoriasis N Engl J Med 2003;349:2014-22.
17. Tyring S, Gordon KB, Poulin Y, et al Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 2007;143:719-26.
18. Reich K, Nestle FO, Papp K, et al; EXPRESS study investigators Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Lancet 2005;366:1367-74.
19. Menter A, Feldman SR, Weinstein GD, et al A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 2007;56:31.e1-15.
20. Leonardi CL, Kimball AB, Papp KA, et al; PHOENIX 1 study investigators Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 2008;371:1665-74.
21. Papp KA, Langley RG, Lebwohl M, et al; PHOENIX 2 study investigators Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 2008;371:1675-84.
22. Kremer JM, Genant HK, Moreland LW, et al Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial Ann Intern Med 2006;144:865-76.
23. Keystone EC, Kavanaugh AF, Sharp JT, et al Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial Arthritis Rheum 2004;50:1400-11.
24. Keystone E, Heijde D, Mason D Jr, et al Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 2008;58:3319-29.
25. Keystone EC, Genovese MC, Klareskog L, et al GO-FORWARD Study Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study Ann Rheum Dis 2009;68:789-96.
26. Smolen JS, Beaulieu A, Rubbert-Roth A, et al OPTION Investigators Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 2008;371:987-97.
27. Smolen J, Landewé RB, Mease P, et al Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study A randomised controlled trial Ann Rheum Dis 2009;68:797-804.
28. Weinblatt ME, Kremer JM, Bankhurst AD, et al A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N EnglJMed 1999;340:253-9.
29. Weinblatt ME, Keystone EC, Furst DE, et al Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum 2003;48:35-45.
30. Emery P, Deodhar A, Rigby WF, et al Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders [SERENE]) Ann Rheum Dis 2010;69:1629-35.
31. Maini R, St Clair EW, Breedveld F, et al Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial ATTRACT Study Group Lancet 1999;354:1932-9.
32. Woolacott N, Hawkins N, Mason A, et al Etanercept and efalizumab for the treatment of psoriasis: a systematic review Health Technol Assess 2006;10:1-233, i-iv.
33. Nixon RM, Bansback N, Brennan A Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis StatMed 2007;26:1237-54.
34. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold- Samsøe B, Saxne T The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review ScandJ Rheumatol 2007;36:411-7.
35. Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH Economic evaluation of systemic therapies for moderate to severe psoriasis Br J Dermatol 2009;160:1264-72.
36. Lu G, Ades AE Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 2004;23:3105-24.
37. Laupacis A, Sackett DL, Roberts RS An assessment of clinically useful measures of the consequences of treatment N Engl J Med 1988;318:1728-33.
38. Yu AP, Johnson S, Wang ST, et al Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease Pharmacoeconomics 2009;27:609-21.
39. Schmitt-Rau K, Rosenbach T, Radtke MA, Augustin M Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis Dermatology 2010;221:236-42.
40. Bucher HC, Guyatt GH, Griffith LE, Walter SD The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 1997;50:683-91.